It also advocates for personalized treatment approaches, such as tailoring interventions based on tau pathology burden and ApoE genotype (Neurologist Branch, Chinese Medical Doctor Association; The Expert Group for Expert Consensus on Disease-Modifying Therapy for Alzheimer’s Disease, 2025; Expert Consensus Review Committee on Disease-Modifying Treatments for Early Alzheimer’s Disease, 2025). The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.